Sartorius Stedim reported strong Q2 20 numbers, with sales up by 21.7% on a cc basis, to €447m, and the EBITDA margin at 30.3%, trumping our estimates as well as consensus. The strength was attributable to 20.2% growth in bioprocessing solutions (BPS). Management upgraded FY20 guidance (growth of 26-30% vs 17-21% earlier; EBITDA margin at 31% vs 30% previously), thanks to the COVID-19-triggered momentum in BPS. Following the strong performance, we will be upgrading our estimates.
23 Jul 2020
Strong Q2 drives FY20 guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q2 drives FY20 guidance upgrade
Sartorius Stedim Biotech SA (0RG8:LON) | 0 0 0.0%
- Published:
23 Jul 2020 -
Author:
Virendra Chauhan -
Pages:
3
Sartorius Stedim reported strong Q2 20 numbers, with sales up by 21.7% on a cc basis, to €447m, and the EBITDA margin at 30.3%, trumping our estimates as well as consensus. The strength was attributable to 20.2% growth in bioprocessing solutions (BPS). Management upgraded FY20 guidance (growth of 26-30% vs 17-21% earlier; EBITDA margin at 31% vs 30% previously), thanks to the COVID-19-triggered momentum in BPS. Following the strong performance, we will be upgrading our estimates.